Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the Austrian multicenter phase II study

Leukemia Research

Volumn 21, Issue 1, 1997, Pages 75-80

  Thaler, Josef ^a   Hilbe, Wolfgang ^a   Apfelbeck, Ute ^b   Linkesch, Werner ^b   Sill, Heinz ^b   Seewann, Heinz ^c   Pont, Jörg ^c   Bernhart, Marianne ^d   Stöger, Manfred ^e   Niessner, Herwig ^c   Abbrederis, Klaus ^c   Geissler, Dietmar ^f   Hausmaninger, Hubert ^c   Lin, Werner ^c   Ludwig, Heinz ^c   Lang, Alois ^c   Duba, Christoph ^g   Fluckinger, Thomas ^a   Greil, Richard ^a   Grünewald, Kurt ^a   Konwalinka, Günther ^a   Niederwieser, Dietger ^a   Fridrik, Michael ^h   more..

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^f GENERAL HOSPITAL KLAGENFURT   (Austria)

^g UNIVERSITY OF INNSBRUCK   (Austria)

^h KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

CML; Interferon alpha; LD ara C

Indexed keywords

ALPHA2 INTERFERON; ALPHA2C INTERFERON; CYTARABINE; HYDROXYUREA;

AGED; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 0031025930     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00084-7     Document Type: Article

References (22)

1. 1. Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Queiber W., Löffler H., Hochhaus A., Heinze B., Georgii A., Bartram C. R., Griebhammer M., Bergmann L., Essers U., Falge C., Queiber U., Meyer P., Schmitz N., Eimermacher H., Walther F., Fett W., Kleeberg U. R., Käbisch A., Nerl C., Zimmermann R., Meuret G., Tichelli A., Kanz L., Tigges F.-J., Schid L., Brockhaus W., Tobler A., Reiter A., Perker M., Emmerich B., Verpoort K., Zankovich R., Wussow P. V., Prümmer O., Thiele J., Buhr T., Carbonell F., Ansari H. and the German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84, 4064.
2. 2. Tura S., Baccarani M., Zuffa E., Russo D., Fanin R., Zaccaria A., Fiacchini M. & the Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl. J. Med. 330, 820.
3. 3. Allan N. C., Richards S. M. & Shepherd P. C. A. on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia (1995) UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 345, 1392.
4. 4. Talpaz M., Kantarjian H. M., McCredie K. B., Trujillo J., Keating M. J. & Gutterman J. U. (1986) Hematologic response and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New Engl. J. Med. 314, 1065.
5. 5. Ozer H., George S. L., Schiffer C. A., Rao K., Rao P. N., Wurster-Hill D. H., Arthur D. D., Powell B., Gottlieb A., Peterson B. A., Rai K., Testa J. R., LeBeau M., Tantravahi R. & Bloomfield C. D. (1993) Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82, 2975.
6. 6. Kloke O., Niederle N., Qiu J. Y., Wandl U., Moritz T., Nagel-Hiemke M., Hawig I., Opalka B., Seeber S. & Becher R. (1993) Impact of interferon alpha-induced cytogenetic improvement of survival in chronic myelogenous leukemia. Br. J. Haematol. 83, 399.
7. 7. Thaler J., Gastl G., Fluckinger T., Niederwieser D., Huber H., Seewann H., Sill H., Lang A., Falk M., Duba C., Utermann G., Kühr T., Aulitzky W. & Huber C. (1996) Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: Long term results of a multicenter phase-II study. Ann. Hematol. 72, 349-355.
8. 8. Kantarjian H. M., Smith T. L., O'Brien S., Beran M., Pierce S., Talpaz M. & the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann. Intern. Med. 122, 254.
9. 9. Spiro T. E., Mattelaer M. A., Efira A. & Stryckmans P. (1981) Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J. Natl. Cancer Inst. 66, 1053.
10. 10. Sokal J. E., Leong S. S. & Gomez G. A. (1987) Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 59, 197.
11. 11. Sokal J. E., Gockerman J. P. & Bigner S. H. (1988) Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leukemia Res. 12, 453.
12. 12. Bonnem E. M. (1987) Alpha interferon: combinations with other antineoplastic modalities. Semin. Oncol. 14, Suppl 2, 48.
13. 13. Guilhot F., Dreyfus B., Desmarest M.-C., Giraud C., Huret J.-L., Brizard A. & Tanzer J. (1989) Combined therapy with interferon and chemotherapy in chronic myelogenous leukemia. Nouv. Rev. Fr. Hematol. 31, 171.
14. 14. Thaler J., Fluckinger T., Huber H., Lang A., Abbrederis C., Seewann H., Silly H., Baldinger C., Duba C., Huber C. & Niederwieser D. (1993) Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low-dose cytosine arabinoside. Leukemia Res. 17, 711.
15. 15. Koeffler H. P. & Golde D. W. (1981) Chronic myelogenous leukemia - new concepts. New Engl. J. Med. 304, 1201.
16. 16. Yunis J. J. (1981) New chromosome techniques in the study of human neoplasia. Human Pathol, 12, 540.
17. 17. Miller A. B., Hoogstraten B., Straquet M. & Winkler A. (1981) Reporting results of cancer treatment. Cancer 47, 207.
18. 18. Silver R. T., Benn P., Szatrowski T. P., Verma R. & Gutfriend A. (1990) Infusional cytosine arabinoside (Ara-C) and recombinant interferon-α (rIFN-α) for the treatment of chronic myeloid leukemia (CML). Proc. ASCO 9, 209.
19. 19. Kantarjian H. M., Keating M. J., Estey E. H., O'Brian S., Pierce S., Beran M., Koller C., Feldman E. & Talpaz M. (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J. Clin. Oncol. 10, 772.
20. 20. Talpaz M., O'Brian S., Kurzrock R., Gutterman J. U., Deisseroth A. & Kantarjian H. M. (1992) Alpha interferon (IFN-α) and chemotherapy combination in early chronic myelogenous leukemia (CML) - a summary of 3 M.D. Anderson studies. Proc. ASCO 11, 274.
21. 21. Arthur C. K. & Ma D. D. F. (1993) Combined interferon alpha-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 89, Suppl 1, 15.
22. 22. Guilhot F., Abgrall J., Harousseau J., Bauters F., Brice R., Dine G., Tilly H., Ifrah N., Cassasus P., Rochant H., Christian B., Guerci A., Lamagnere J., Le Prise P., Duclos B. & Tanzer J. (1993) A multicenter randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-C) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary results. Leukemia Lymphoma 11, Suppl 1, 181.